<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        15-584-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LUKRA 4MG CHEWABLE TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NEOPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Lukra 4 mg Paediatric Chewable Tablets is<br />Lukra 4 mg Paediatric Chewable Tablets is a leukotriene receptor antagonist<br />that blocks substances called leukotrienes.<br />How Lukra 4 mg Paediatric Chewable Tablets work<br />Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking<br />leukotrienes, Lukra 4 mg Paediatric Chewable Tablets improve asthma<br />symptoms and helps control asthma.<br />When Lukra 4 mg Paediatric Chewable Tablets should be used<br />Your doctor has prescribed Lukra 4 mg Paediatric Chewable Tablets to treat<br />your child&rsquo;s asthma, preventing asthma symptoms during the day and night.<br />&bull; Lukra 4 mg Paediatric Chewable Tablets are used for the treatment of 2 to<br />5 year old patients who are not adequately controlled on their medication<br />and need additional therapy.<br />&bull; Lukra 4 mg Paediatric Chewable Tablets may also be used as an<br />alternative treatment to inhaled corticosteroids for 2 to 5 year old patients<br />who have not recently taken oral corticosteroids for their asthma and have<br />shown that they are unable to use inhaled corticosteroids.<br />&bull; Lukra 4 mg Paediatric Chewable Tablets also helps prevent the narrowing<br />of airways triggered by exercise for patients 2 years of age and older.<br />Your doctor will determine how Lukra 4 mg Paediatric Chewable Tablets should<br />be used depending on the symptoms and severity of your child&#39;s asthma.<br />What is asthma?<br />Asthma is a long-term disease.<br />Asthma includes:<br />&bull; difficulty breathing because of narrowed airways. This narrowing of airways<br />worsens and improves in response to various conditions.<br />&bull; sensitive airways that react to many things, such as cigarette smoke,<br />pollen, cold air, or exercise.<br />&bull; swelling (inflammation) in the lining of the airways.<br />Symptoms of asthma include: Coughing, wheezing, and chest tightness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies your child has now or<br />has had.<br />Do not give Lukra 4 mg Paediatric Chewable Tablets to your child<br />&bull; if he/she is allergic to montelukast or any of the other ingredients of this<br />medicine (listed in section 6).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before you give Lukra 4 mg Paediatric<br />Chewable Tablets to your child.<br />&bull; If your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.<br />&bull; Oral Montelukast is not meant to treat acute asthma attacks. If an attack<br />occurs, follow the instructions your doctor has given you for your child.<br />Always have your child&rsquo;s inhaled rescue medicine for asthma attacks with you.<br />&bull; It is important that your child take all asthma medications prescribed by<br />your doctor. Lukra 4 mg Paediatric Chewable Tablets should not be used<br />instead of other asthma medications your doctor has prescribed for your<br />child.<br />&bull; If your child is on anti-asthma medicines, be aware that if he/she develops<br />a combination of symptoms such as flu-like illness, pins and needles or<br />numbness of arms or legs, worsening of pulmonary symptoms, and/or<br />rash, you should consult your doctor.<br />&bull; Your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory<br />medicines (also known as non-steroidal anti-inflammatory drugs or<br />NSAIDs)if they make his/her asthma worse.<br />Children and adolescents<br />Do not give this medicine to children less than 2 years of age.<br />There are different form(s) of montelukast available for paediatric patients<br />under 18 years of age based on age range.<br />Other medicines and Lukra 4 mg Paediatric Chewable Tablets<br />Tell your doctor or pharmacist if your child is taking or has recently been given<br />or might be given any other medicines including those obtained without a<br />prescription.<br />Some medicines may affect how Lukra 4 mg Paediatric Chewable Tablets<br />work, or Lukra 4 mg Paediatric Chewable Tablets may affect how your child&rsquo;s<br />other medicines work.<br />Tell your doctor if your child is taking the following medicines before starting<br />Lukra 4 mg Paediatric Chewable Tablets:<br />&bull; phenobarbital (used for treatment of epilepsy)<br />&bull; phenytoin (used for treatment of epilepsy)<br />&bull; rifampicin (used to treat tuberculosis and some other infections)<br />Lukra 4 mg Paediatric Chewable Tablets with food and drink<br />Lukra 4 mg Paediatric Chewable Tablets should not be taken immediately with<br />food; they should be taken at least 1 hour before or 2 hours after food.<br />Pregnancy and breast-feeding<br />This subsection is not applicable for the Lukra 4 mg Paediatric Chewable<br />Tablets since they are intended for use in children 2 to 5 years of age.<br />Driving and using machines<br />This subsection is not applicable for the Lukra 4 mg Paediatric Chewable<br />Tablets since they are intended for use in children 2 to 5 years of age, however<br />the following information is relevant to the active ingredient, montelukast.<br />Lukra 4 mg Paediatric Chewable Tablets are not expected to affect your ability<br />to drive a car or operate machinery. However, individual responses to<br />medication may vary. Certain side effects (such as dizziness and drowsiness)<br />that have been reported with Montelukast may affect some patient&rsquo;s ability to<br />drive or operate machinery.<br />Lukra 4 mg Paediatric Chewable Tablets contain aspartame, a source of<br />phenylalanine<br />If your child has phenylketonuria (a rare, hereditary disorder of the metabolism)<br />you should take into account that each 4 mg chewable tablet contains<br />phenylalanine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always have your child take this medicine exactly as your doctor or pharmacist<br />has told you. Check with your child&rsquo;s doctor or pharmacist if you are not sure.<br />&bull; This medicine is to be given to a child under adult supervision. For children<br />who have problems consuming a chewable tablet, an oral granule<br />formulation of montelukast is available.<br />&bull; Your child should take only one Lukra 4 mg Paediatric Chewable Tablet<br />once a day as prescribed by your doctor.<br />&bull; It should be taken even when your child has no symptoms or if he/she has<br />an acute asthma attack.<br />For children 2 to 5 years of age:<br />The recommended dose is one 4 mg chewable tablet daily to be taken in the<br />evening.<br />If your child is taking Lukra 4 mg Paediatric Chewable Tablets, be sure that<br />he/she does not take any other medicines that contain the same active<br />ingredient, montelukast.<br />This medicine is for oral use.<br />The tablets are to be chewed before swallowing.<br />Lukra 4 mg Paediatric Chewable Tablets should not be taken immediately with<br />food; it should be taken at least 1 hour before or 2 hours after food.<br />If your child takes more Lukra 4 mg Paediatric Chewable Tablets than<br />he/she should<br />Contact your child&rsquo;s doctor immediately for advice.<br />There were no side effects reported in the majority of overdose reports. The&nbsp;most frequently occurring symptoms reported with overdose in adults and<br />children included abdominal pain, sleepiness, thirst, headache, vomiting and<br />hyperactivity.<br />If you forget to give Lukra 4 mg Paediatric Chewable Tablets to your child<br />Try to give Lukra 4 mg Paediatric Chewable Tablets as prescribed. However, if<br />your child misses a dose, just resume the usual schedule of one chewable<br />tablet once daily.<br />Do not give a double dose to make up for a forgotten dose.<br />If your child stops taking Lukra 4 mg Paediatric Chewable Tablets<br />Lukra 4 mg Paediatric Chewable Tablets can treat your child&rsquo;s asthma only if<br />he/she continues taking it.<br />It is important for your child to continue taking Lukra 4 mg Paediatric Chewable<br />Tablets for as long as your doctor prescribes. It will help control your child&rsquo;s<br />asthma.<br />If you have any further questions on the use of this medicine, ask your child&rsquo;s<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />In clinical studies with Montelukast 4 mg chewable tablets, the most commonly<br />reported side effects (occurring in at least 1 of 100 patients and less than 1 of<br />10 paediatric patients treated) thought to be related to Montelukast 4 mg<br />chewable tablets were:<br />&bull; abdominal pain<br />&bull; thirst<br />Additionally, the following side effect was reported in clinical studies with<br />Montelukast 10 mg film coated tablets and 5 mg chewable tablets:<br />&bull; headache<br />These were usually mild and occurred at a greater frequency in patients treated<br />with Montelukast than placebo (a pill containing no medication).<br />The frequency of possible side effects listed below is defined using the<br />following convention:<br />Very common: may affect more than 1 in 10 people<br />Common: may affect up to 1 in 10 people<br />Uncommon: may affect up to 1 in 100 people<br />Rare: may affect up to 1 in 1,000 people<br />Very rare: may affect up to 1 in 10,000 people<br />Not known: frequency cannot be estimated from the available data<br />Additionally, while the medicine has been on the market, the following have<br />been reported:<br />&bull; upper respiratory infection (Very common)<br />&bull; increased bleeding tendency (Rare)<br />&bull; allergic reactions including swelling of the face, lips, tongue, and/or throat<br />which may cause difficulty in breathing or swallowing (Uncommon)<br />&bull; behaviour and mood related changes [dream abnormalities, including<br />nightmares, trouble sleeping, sleepwalking, irritability, feeling anxious,<br />restlessness, agitation including aggressive behaviour or hostility,<br />depression (Uncommon); tremor, disturbance in attention, memory<br />impairment (Rare); hallucinations, disorientation, suicidal thoughts and<br />actions (Very rare)]<br />&bull; dizziness, drowsiness, pins and needles/numbness, seizure (Uncommon)<br />&bull; palpitations (Rare)<br />&bull; nosebleed (Uncommon), swelling (inflammation) of the lungs (Very rare)<br />&bull; diarrhoea, nausea, vomiting (Common); dry mouth, indigestion<br />(Uncommon)<br />&bull; hepatitis (inflammation of the liver) (Very rare)<br />&bull; rash (Common); bruising, itching, hives (Uncommon); tender red lumps<br />under the skin most commonly on your shins (erythema nodosum), severe<br />skin reactions (erythema multiforme) that may occur without warning (Very<br />rare)<br />&bull; joint or muscle pain, muscle cramps (Uncommon)<br />&bull; fever (Common); weakness/tiredness, feeling unwell, swelling (Uncommon)<br />In asthmatic patients treated with montelukast, very rare cases of a combination<br />of symptoms such as flu-like illness, pins and needles or numbness of arms and<br />legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss<br />syndrome) have been reported. You must tell your doctor right away if your<br />child gets one or more of these symptoms (See section 2).<br />If your child gets any side effects, talk to your doctor, pharmacist or nurse. This<br />includes any possible side effects not listed in this leaflet.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the carton<br />and blister after EXP. The expiry date refers to the last day of that month.<br />&bull; Store below 30&deg;C.<br />&bull; Store in the original package in order to protect from light and moisture.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Lukra 4 mg Paediatric Chewable Tablets contain?<br />The active substance is montelukast.<br />&bull; Each chewable tablet contains Montelukast Sodium equivalent to 4 mg of<br />Montelukast.<br />&bull; The other ingredients are Mannitol, Croscarmellose Sodium, Hydroxypropyl<br />Cellulose, Ferric Oxide, Cellulose Microcrystalline, Aspartame, ART Cherry<br />Flavor (SD#594) and Magnesium Stearate.<br />What Lukra 4 mg Paediatric Chewable Tablets look like?<br />Light pink to pink coloured, speckled, oval, biconvex shaped, chewable tablets,<br />debossed with &#39;MS4&#39; on one side and plain on other side.<br />How supplied:<br />Lukra 4 mg Paediatric Chewable Tablets are supplied in Blister pack.<br />&bull; Pack of 30 tablets (3x10&rsquo;s blisters).<br />&bull; Pack of 100 tablets (10x10&rsquo;s blisters).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Lukra 4 mg Paediatric Chewable Tablets contain?
The active substance is montelukast.
• Each chewable tablet contains Montelukast Sodium equivalent to 4 mg of
Montelukast.
• The other ingredients are Mannitol, Croscarmellose Sodium, Hydroxypropyl
Cellulose, Ferric Oxide, Cellulose Microcrystalline, Aspartame, ART Cherry
Flavor (SD#594) and Magnesium Stearate.
What Lukra 4 mg Paediatric Chewable Tablets look like?
Light pink to pink coloured, speckled, oval, biconvex shaped, chewable tablets,
debossed with 'MS4' on one side and plain on other side.
How supplied:
Lukra 4 mg Paediatric Chewable Tablets are supplied in Blister pack.
• Pack of 30 tablets (3x10’s blisters).
• Pack of 100 tablets (10x10’s blisters).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Neopharma&nbsp;</p><p>Plot A-1 89-95, ICAD, Mussafah,<br />P.O. Box 72900, Abu Dhabi, UAE.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>قرص لوكرا ٤ ملجم مضغ للأطفال هو مضاد مستقبل الليوكوترين الذي يحصر مواداً<br />تدعى الليكوترينات.<br />كيف تعمل أقراص لوكرا ٤ ملجم مضغ للأطفال<br />تسبب الليكوترينات تض ّ يق وتورم المسالك الهوائية في الرئتين. ومن خلال حصر<br />الليكوترينات، تُقلل أقراص لوكرا ٤ ملجم مضغ للأطفال أعراض الربو وتساعد في<br />التحكم<br />في هذا المرض.<br />متى يجب استخدام أقراص لوكرا ٤ ملجم مضغ للأطفال<br />وصف لك طبيبك أقراص لوكرا ٤ ملجم مضغ للأطفال لعلاج الربو عند طفلك،<br />حيث تمنع ظهور أعراض الربو خلال الليل والنهار.<br />&bull; تستخدم أقراص لوكرا ٤ ملجم مضغ للأطفال لعلاج المرضى الأطفال من ٢ إلى ٥<br />سنوات الذين لا تكفي أدويتهم للتحكم في المرض ويحتاجون لعلاج إضافي.<br />&bull; قد تُستخدم أقراص لوكرا ٤ ملجم مضغ للأطفال كعلاج بديل للستيرويدات<br />٥ سنوات الذين لم يتناولوا مؤخراً - القشرية المستنشقة للأطفال من عمر ٢<br />ستيرويدات قشرية عن طريق الفم لعلاج الربو وتبين أنهم غير قادرين على استخدام<br />الستيرويدات القشرية المستنشقة.<br />&bull; تساعد أقراص لوكرا ٤ ملجم مضغ للأطفال أيضاً على منع تض ّ يق المسالك<br />الهوائية الذي يثيره اﻟﻤﺠهود البدني للأطفال من عمر سنتين وأكثر. سيحدد طبيبك<br />كيفية استخدام أقراص لوكرا ٤ ملجم مضغ للأطفال بحسب الأعراض و ِ حدة الربو<br />عند طفلك.<br />ما هو الربو؟<br />الربو مرض طويل المدى.<br />يتضمن الربو:<br />&bull; صعوبة في التنفس بسبب تض ّ يق المسالك الهوائية. يسوء ويتحسن هذا التض ّ يق<br />في المسالك الهوائية بحسب الاستجابة لظروف مختلفة.<br />&bull; المسالك الهوائية الحساسة التي تتفاعل مع أشياء عديدة، مثل دخان السجائر،<br />أو اللقاح، أو الهواء البارد، أو اﻟﻤﺠهود البدني.<br />&bull; تورم (التهاب) بطانة المسالك الهوائية.<br />تتضمن أعراض الربو: سعال، وصفير، وضيق الصدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٢. ما الذي يجب أن تعرفه قبل إعطاء طفلك أقراص لوكرا ٤ ملجم مضغ للأطفال<br />أخبر طبيبك بشأن أي مشاكل طبية أو حساسية يعاني منها طفلك الآن<br />أو سبق له الإصابة بها.<br />لا تع ِ ط أقراص لوكرا ٤ ملجم مضغ للأطفال لطفلك<br />&bull; إذا كان/كانت مصاباً/مصابة بحساسية لمادة المونتيلوكاست أو أي من مكونات هذا<br />.( الدواء (المدرجة في القسم ٦<br />التحذيرات والاحتياطات<br />تحدث إلى طبيبك أو الصيدلي قبل إعطاء أقراص لوكرا ٤ ملجم مضغ للأطفال<br />لطفلك.<br />&bull; إذا ساء الربو أو التنفس عند طفلك، أخبر طبيبك على الفور.<br />&bull; مادة المونتيلوكاست التي يتم تناولها عن طريق الفم غير مخصصة لعلاج أزمات<br />الربو الحادة. في حالة حدوث أزمة، اتبع التعليمات التي وصفها الطبيب لطفلك.<br />اجعل الدواء المستنشق الخاص بطفلك لعلاج أزمات الربو الطارئة بحوزتك دائماً.<br />&bull; من الهام أن يتناول طفلك جميع أدوية الربو التي وصفها طبيبك. يجب عدم<br />استخدام أقراص لوكرا ٤ ملجم مضغ للأطفال كبديل عن أدوية الربو الأخرى التي<br />وصفها الطبيب لطفلك.<br />&bull; إذا كان طفلك يتناول أدوية مضادة للربو، يجب الانتباه إذا ظهر عليه/عليها مجموعة<br />أعراض تشبه مرض الإنفلونزا، أو وخز دبابيس وإبر، أو خدر في الذراعين أو الساقين، أو<br />تدهور الأعراض الرئوية، و/أو طفح جلدي، فيجب عليك استشارة الطبيب.<br />&bull; يجب على طفلك عدم تناول حمض أسيتيل ساليسيليك (أسبرين) أو الأدوية المضادة<br />للالتهابات (تُعرف أيضاً بالعقاقير غير السترويدية المضادة للالتهابات أو (مضادات<br />الالتهاب اللاستيرويدية) إذا جعلت الأزمة عند طفلك/طفلتك أسوأ.<br />الأطفال والمراهقون<br />لا تعط هذا الدواء للأطفال الأصغر من سنتين.<br />تتوفر تركيبات أخرى من مادة المونتيلوكاست للأطفال المرضى أقل من ١٨ عاماً بحسب<br />الفئة العمرية.<br />الأدوية الأخرى وأقراص لوكرا ٤ ملجم مضغ للأطفال<br />أخبر طبيبك أو الصيدلي إذا ما كان طفلك يتناول أو تناول مؤخراً أو قد يتناول أي أدوية<br />أخرى، بما في ذلك تلك الأدوية التي تُصرف بدون وصفة طبية.<br />قد تؤثر بعض الأدوية على الطريقة التي تعمل بها أقراص لوكرا ٤ ملجم مضغ<br />للأطفال، أو قد تؤثر أقراص لوكرا ٤ ملجم مضغ للأطفال على الطريقة التي تعمل بها<br />أدوية طفلك الأخرى.<br />أخبر طبيبك إذا ما كان طفلك يتناول الأدوية التالية قبل بدء العلاج بأقراص لوكرا ٤<br />ملجم مضغ للأطفال:<br />&bull; فينوباربيتال (يستخدم لعلاج الصرع)<br />&bull; فينيتوين (يستخدم لعلاج الصرع)<br />&bull; ريفامبيسين (يُستخدم في علاج السل وبعض الالتهابات الأخرى)<br />أقراص لوكرا ٤ ملجم مضغ للأطفال مع الطعام والشراب<br />يجب عدم تناول أقراص لوكرا ٤ ملجم مضغ للأطفال في نفس الوقت مع الطعام، بل<br />يجب تناولها قبل ساعة من تناول الطعام على الأقل أو بعده بساعتين.<br />الحمل والرضاعة الطبيعية<br />لا ينطبق هذا القسم الفرعي على أقراص لوكرا ٤ ملجم مضغ للأطفال حيث أنها<br />مخصصة لعلاج الأطفال بعمر سنتين إلى ٥ سنوات.<br />القيادة واستخدام الآلات<br />لا ينطبق هذا القسم الفرعي على أقراص لوكرا ٤ ملجم مضغ للأطفال حيث أنها<br />مخصصة لعلاج الأطفال بعمر سنتين إلى ٥ سنوات، إلا أن المعلومات التالية متصلة<br />بالمكون الفعال، وهي مادة المونتيلوكاست.<br />من غير المتوقع أن تؤثر أقراص لوكرا ٤ ملجم مضغ للأطفال على قدرتك على القيادة<br />أو تشغيل أي آلة. إلا أن الاستجابات الفردية للدواء قد تتباين. قد تؤثر آثار جانبية محددة<br />(مثل ال ّ دوار والنعاس) ارتبطت باستخدام مادة المونتيلوكاست على قدرة المريض على<br />القيادة أو تشغيل الآلات.<br />تحتوي أقراص لوكرا ٤ ملجم مضغ للأطفال على الأسبارتام، وهو أحد مصادر<br />الفينيل ألانين.<br />إذا كان طفلك مصاباً ب ِ بي َ ل ُ ة الفينيل كيتون (اضطراب أيضي وراثي نادر)، يجب عليك أن<br />تأخذ في الاعتبار أن كل قرص مضغ ٤ ملجم مضغ للأطفال يحتوي على مادة الفينيل<br />ألانين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تأكد دائماً من تناول طفلك لهذا الدواء على النحو الذي يصفه طبيبك أو الصيدلي.<br />استشر طبيب طفلك أو الصيدلي إذا لم تكن متأك ً دا.<br />&bull; ينبغي إعطاء هذا الدواء للأطفال بإشراف أحد البالغين. وللأطفال الذين يواجهون<br />صعوبة في تناول أقراص المضغ، تتوفر تركيبة حبيبية من مادة المونتيلوكاست.<br />&bull; يجب أن يتناول طفلك قرص مضغ واحد فقط من لوكرا ٤ ملجم مضغ للأطفال مرة<br />واحدة يومياً على النحو الذي يصفه الطبيب.<br />&bull; يجب تناوله حتى عند عدم ظهور أي أعراض أو عند إصابة طفلك/طفلتك بأزمة ربو<br />حادةللأطفال بعمر سنتين إلى ٥ سنوات:<br />الجرعة الموصى بها هي قرص مضغ واحد ٤ ملجم مرة واحدة يومياً في المساء.<br />إذا كان طفلك يتناول أقراص لوكرا ٤ ملجم مضغ للأطفال، تأكد أنه/أنها لا<br />يتناول/تتناول أي أدوية أخرى تحتوى على نفس المكون الفعال، وهي مادة المونتيلوكاست.<br />يُتناول هذا الدواء عن طريق الفم.<br />يجب مضغ الأقراص قبل ابتلاعها.<br />يجب عدم تناول أقراص لوكرا ٤ ملجم مضغ للأطفال مع الطعام في نفس الوقت، بل<br />يجب تناولها قبل ساعة على الأقل من تناول الطعام أو بعده بساعتين.<br />في حالة تناول طفلك كمية أكثر من اللازم من أقراص لوكرا ٤ ملجم مضغ<br />للأطفال،<br />يجب عليك الاتصال بطبيب طفلك على الفور لاستشارته. لم ترد أي آثار جانبية في<br />أغلبية تقارير الجرعة المفرطة. تضمنت الأعراض الأكثر شيوعاً التي أُبلغ عنها في حالة<br />الجرعات المفرطة في البالغين والأطفال الشعور بألم في البطن، والنعاس، والعطش،<br />والصداع، والقيء، والنشاط المفرط.</p><p>إذا نسيت إعطاء أقراص لوكرا ٤ ملجم مضغ للأطفال لطفلك<br />حاول إعطاء أقراص لوكرا ٤ ملجم مضغ للأطفال على النحو الموصوف. في حالة ف ّ وت<br />طفلك جرعة، واصل النظام المعتاد من قرص مضغ واحد يومياً.<br />لا تعط طفلك جرعة مضاعفة لتعويض الجرعة التي نسيتها.<br />في حالة انقطاع الطفل عن تناول أقراص لوكرا ٤ ملجم مضغ للأطفال<br />يمكن لأقراص لوكرا ٤ ملجم مضغ للأطفال علاج الربو عند طفلك إذا داوم/داومت على<br />تناولها. من المهم لطفلك المداومة على تناول أقراص لوكرا ٤ ملجم مضغ للأطفال<br />للمدة التي يصفها الطبيب، حيث يساعد ذلك على التحكم في الربو عند طفلك. إن<br />كان لديك أي استفسارات أخرى حول استخدام هذا الدواء فاسأل طبيب طفلك أو<br />الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية يمكن لهذا الدواء أن يسبب آثاراً جانبية، على الرغم من أنه ليس<br />بالضرورة أن يعاني منها الجميع.<br />في الدراسات الإكلينيكية على مونتيلوكاست أقراص مضغ ٤ ملجم. كانت الآثار<br />الجانبية<br />الأكثر شيوعاً (تحدث على الأقل في ١ من كل ١٠٠ مريض وأقل من ١ في ١٠ مرضى<br />أطفال يتلقون العلاج) التي يُعتقد أنها ذات صلة بمونتيلوكاست أقراص مضغ ٤ ملجم<br />هي:<br />&bull; ألم البطن<br />&bull; عطش<br />بالإضافة إلى ذلك، أٌبلغ عن الآثار الجانبية التالية في الدراسات الإكلينيكية<br />لمونتيلوكاست أقراص مغلفة ١٠ ملجم وأقراص المضغ ٥ ملجم:<br />&bull; الصداع<br />كانت هذه الآثار في الأغلب طفيفة وظهرت بمعدل أعلى على المرضى الذين يتلقون<br />العلاج بمادة المونتيلوكاست مقارنة بالبلاسيبو (أقراص لا تحتوي على أي دواء).<br />ُ حدد معدل ظهور الآثار الجانبية المحتملة الواردة أدناه باستخدام الاصطلاحات التالية:<br />شائعة جداً: قد تؤثر على أكثر من ١ من كل ١٠ أشخاص<br />شائعة: قد تؤثر على ١ من كل ١٠ أشخاص<br />غير شائعة: قد تؤثر على ١ من كل ١٠٠ شخص<br />نادرة: قد تؤثر على ١ من كل ١٠٠٠ شخص<br />نادرة جداً: قد تؤثر على ١ من كل ١٠٠٠٠ شخص<br />غير معروف: لا يمكن تقدير مدى التكرار من البيانات المتوفرة بالإضافة إلى ذلك، في<br />الوقت الذي كان فيه الدواء مطروحاً في الأسواق، تم الإبلاغ عن الآثار الجانبية التالية:<br />&bull; التهاب في الجزء العلوي التنفسي (شائع جداً)<br />&bull; ميل متزايد للنزيف (نادر)<br />&bull; ردود فعل تحسسية تتضمن تورم الوجه، والشفتين، واللسان، و/أو الحلق مما قد يسبب<br />صعوبة في التنفس أو البلع (غير شائع)<br />&bull; تغيرات مزاجية وسلوكية [أحلام مضطربة، تشمل الكوابيس، وصعوبة في النوم،<br />والسير أثناء النوم، والتهيج، والشعور بالقلق، والتململ، والهياج بما في ذلك السلوك<br />العدائي أو العدوانية، والاكتئاب (غير شائع)؛ الرعشة، واضطراب الانتباه، وضعف<br />الذاكرة (نادر)؛ هلوسة، وتشوش، وأفكار وتصرفات انتحارية (نادر جداً)]<br />&bull; دوّار، ونعاس، ووخز بالإبر والدبابيس/خدر، ونوبات (غير شائع)<br />&bull; خفقان (نادر)<br />&bull; النزف الأنفي (غير شائع)، وتورم (التهاب) الرئتين (نادر جداً)<br />&bull; إسهال، وغثيان، وقيء (شائع)، وجفاف الفم، وعسر الهضم (غير شائع)<br />&bull; التهاب كبدي (التهاب الكبد) (نادر جداً)<br />&bull; طفح جلدي (شائع)، وتكدم، وحكة، وشرى (غير شائع)، وكتل حمراء لينة تحت الجلد<br />في الأغلب في مقدمة السيقان (الحمامى العقدية)، وردود فعل جلدية حادة (الحمامى<br />متعددة الأشكال) التي قد تحدث بدون إنذار (نادر جداً)<br />&bull; ألم مفصلي أو عضلي، وتشنجات عضلية (غير شائع)<br />&bull; حمى (شائع)، وضعف/إجهاد، وشعور بالاعتلال، وتورم (غير شائع) في المرضى المصابين<br />بالربو الذين يتلقون العلاج بمادة المونتيلوكاست، أُبلغ عن حالات نادرة جداً من<br />مجموعة أعراض تشبه مرض الإنفلونزا، أو وخز دبابيس وإبر، أو خدر في الذراعين أو<br />الساقين، أو تدهور أعراض رئوية و/أو طفح جلدي (متلازمة شيرغ ستراوس). يجب<br />عليك إبلاغ الطبيب على الفور في حال ظهور واحد أو أكثر من هذه الأعراض على<br />.( طفلك (راجع القسم ٢<br />إذا ظهرت على طفلك أي أعراض جانبية، فتحدث مع طبيبك أو الصيدلي، أو الممرضة.<br />وذلك يتضمن أي أعراض جانبية محتملة غير مدرجة في هذه النشرة.<br />للإبلاغ عن الأعراض الجانبية:<br />&bull; المملكة العربية السعودية:</p><p>&bull; دول الخليج الأخرى:<br />الرجاء الإتصال بالمؤسسات والهيئات الوطنية لكل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٥. كيفية تخزين أقراص لوكرا ٤ ملجم مضغ للأطفال<br />&bull; يحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.<br />&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العلبة الكرتونية<br />يشير تاريخ انتهاء الصلاحية .(EXP) &quot; والشريط بعد عبارة &quot;تاريخ انتهاء الصلاحية<br />إلى آخر يوم من ذلك الشهر.<br />&bull; يخزن في درجة حرارة أقل من ٣٠ &deg; درجة مئوية.<br />&bull; يُحفظ في العبوة الأصلية لحمايته من الضوء والرطوبة.<br />&bull; لا تتخلص من أي أدوية في ماء الصرف الصحي أو مع اﻟﻤﺨلفات المنزلية. اسأل الصيدلي<br />عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات<br />في الحفاظ على البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٦. معلومات إضافية<br />ما هي محتويات أقراص لوكرا ٤ ملجم مضغ للأطفال؟<br />المادة الفعالة هي المونتيلوكاست.<br />&bull; يحتوي كل قرص مضغ على مونتيلوكاست الصوديوم بما يعادل ٤ ملجم من مادة<br />المونتيلوكاست.<br />&bull; المكونات الأخرى هي مانيتول، كروس كارميلوز الصوديوم، هيدروكسي بروبيل<br />السليولوز، أكسيد الحديديك، سيليولوز دقيق التبلور، أسبارتام، نكهة كرز صناعية<br />وستيارات المغنيسيوم. (#SD٥٩٤)<br />كيف تبدو أقراص لوكرا ٤ ملجم مضغ للأطفال؟<br />أقراص مضغ منقطة، وردية فاتحة إلى وردية، بيضاوية محدبة من الجانبين، ومحفور<br />والجانب الآخر فارغ. &quot;MS على أحد جانبيها &quot; 4<br />كيف يتم توريدها:<br />تباع أقراص لوكرا ٤ ملجم مضغ للأطفال في عبوات تحتوي على شرائط.<br />&bull; علبة تحتوي على ٣٠ قرصاً ( ٣ شرائط يحتوي كل منها على ١٠ أقراص).<br />&bull; علبة تحتوي على ١٠٠ قرص ( ١٠ شرائط يحتوي كل منها على ١٠ أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>٦. معلومات إضافية<br />ما هي محتويات أقراص لوكرا ٤ ملجم مضغ للأطفال؟<br />المادة الفعالة هي المونتيلوكاست.<br />&bull; يحتوي كل قرص مضغ على مونتيلوكاست الصوديوم بما يعادل ٤ ملجم من مادة<br />المونتيلوكاست.<br />&bull; المكونات الأخرى هي مانيتول، كروس كارميلوز الصوديوم، هيدروكسي بروبيل<br />السليولوز، أكسيد الحديديك، سيليولوز دقيق التبلور، أسبارتام، نكهة كرز صناعية<br />وستيارات المغنيسيوم. (#SD٥٩٤)<br />كيف تبدو أقراص لوكرا ٤ ملجم مضغ للأطفال؟<br />أقراص مضغ منقطة، وردية فاتحة إلى وردية، بيضاوية محدبة من الجانبين، ومحفور<br />والجانب الآخر فارغ. &quot;MS على أحد جانبيها &quot; 4<br />كيف يتم توريدها:<br />تباع أقراص لوكرا ٤ ملجم مضغ للأطفال في عبوات تحتوي على شرائط.<br />&bull; علبة تحتوي على ٣٠ قرصاً ( ٣ شرائط يحتوي كل منها على ١٠ أقراص).<br />&bull; علبة تحتوي على ١٠٠ قرص ( ١٠ شرائط يحتوي كل منها على ١٠ أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>نيوفارما&nbsp;</p><p>٩٥ ، مدينة أبوظبي -٨٩ قطعة رقم إيه- ١<br />الصناعية، مصفح، ص.ب. ٧٢٩٠٠ ، أبوظبي، إ.ع.م.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lukra Paediatric Chewable Tablets 4 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each chewable tablets contains 4 mg Montelukast Sodium. ‘For full list of excipients, see
section 6.1’
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chewable Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast Sodium is indicated in the treatment of asthma as add-on therapy in those 2<br />to 5-year-old patients with mild to moderate persistent asthma who are inadequately<br />controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short-acting &beta;-agonists<br />provide inadequate clinical control of asthma.<br />Montelukast Sodium may also be an alternative treatment option to low-dose inhaled<br />corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a<br />recent history of serious asthma attacks that required oral corticosteroid use, and who<br />have demonstrated that they are not capable of using inhaled corticosteroids.<br />Montelukast Sodium is also indicated in the prophylaxis of asthma from 2 years of age and<br />older in which the predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />This medicinal product is to be given to a child under adult supervision. For children who<br />have problems consuming a chewable tablet, a granule formulation is available.<br />The recommended dose for paediatric patients 2-5 years of age is one 4 mg chewable<br />tablet daily to be taken in the evening. If taken in connection with food, Montelukast<br />Sodium should be taken 1 hour before or 2 hours after food. No dosage adjustment within<br />this age group is necessary.&nbsp;General recommendations<br />The therapeutic effect of Montelukast Sodium on parameters of asthma control occurs<br />within one day. Patients should be advised to continue taking Montelukast Sodium even if<br />their asthma is under control, as well as during periods of worsening asthma.<br />No dosage adjustment is necessary for patients with renal insufficiency, or mild to<br />moderate hepatic impairment. There are no data on patients with severe hepatic<br />impairment. The dosage is the same for both male and female patients.<br />Montelukast Sodium as an alternative treatment option to low-dose inhaled<br />corticosteroids for mild, persistent asthma<br />Montelukast is not recommended as monotherapy in patients with moderate persistent<br />asthma. The use of montelukast as an alternative treatment option to low-dose inhaled<br />corticosteroids for children with mild persistent asthma should only be considered for<br />patients who do not have a recent history of serious asthma attacks that required oral<br />corticosteroid use and who have demonstrated that they are not capable of using inhaled<br />corticosteroids (see section 4.1). Mild persistent asthma is defined as asthma symptoms<br />more than once a week but less than once a day, nocturnal symptoms more than twice a<br />month but less than once a week, normal lung function between episodes. If satisfactory<br />control of asthma is not achieved at follow-up (usually within one month), the need for<br />an additional or different anti-inflammatory therapy based on the step system for asthma<br />therapy should be evaluated. Patients should be periodically evaluated for their asthma<br />control.<br />Montelukast Sodium as prophylaxis of asthma for 2 to 5 year old patients in whom the<br />predominant component is exercise-induced bronchoconstriction<br />In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant<br />manifestation of persistent asthma that requires treatment with inhaled corticosteroids.<br />Patients should be evaluated after 2 to 4 weeks of treatment with montelukast. If<br />satisfactory response is not achieved, an additional or different therapy should be<br />considered.<br />Therapy with Montelukast Sodium in relation to other treatments for asthma<br />When treatment with Montelukast Sodium is used as add-on therapy to inhaled<br />corticosteroids, Montelukast Sodium should not be abruptly substituted for inhaled<br />corticosteroids.&nbsp;10 mg film-coated tablets are available for adults and adolescents 15 years of age and<br />older.<br />Paediatric population<br />Do not give Montelukast Sodium 4 mg chewable tablets to children less than 2 years of<br />age. The safety and efficacy of Montelukast Sodium 4 mg chewable tablets in children<br />less than 2 years of age has not been established.<br />5 mg chewable tablets are available for paediatric patients 6 to 14 years of age.<br />4 mg granules are available for paediatric patients 6 months to 5 years of age.<br />Method of administration<br />Oral use.<br />The tablets are to be chewed before swallowing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks<br />and to keep their usual appropriate rescue medication for this purpose readily available.<br />If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients<br />should seek their doctors&#39; advice as soon as possible if they need more inhalations of<br />short-acting &beta;-agonists than usual.<br />Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.<br />There are no data demonstrating that oral corticosteroids can be reduced when<br />montelukast is given concomitantly.<br />In rare cases, patients on therapy with anti-asthma agents including montelukast may<br />present with systemic eosinophilia, sometimes presenting with clinical features of<br />vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated<br />with systemic corticosteroid therapy. These cases have been sometimes associated with<br />the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship<br />with leukotriene receptor antagonism has not been established, physicians should be<br />alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac<br />complications, and/or neuropathy presenting in their patients. Patients who develop<br />these symptoms should be reassessed and their treatment regimens evaluated.&nbsp;Treatment with montelukast does not alter the need for patients with aspirin-sensitive<br />asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.<br />Montelukast Sodium contains aspartame, a source of phenylalanine. Patients with<br />phenylketonuria should take into account that each 4 mg chewable tablet contains<br />phenylalanine in an amount equivalent to 0.674 mg phenylalanine per dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis<br />and chronic treatment of asthma. In drug-interactions studies, the recommended clinical<br />dose of montelukast did not have clinically important effects on the pharmacokinetics of<br />the following medicinal products: theophylline, prednisone, prednisolone, oral<br />contraceptives (ethinyl oestradiol/norethindrone 35/1), terfenadine, digoxin and<br />warfarin.<br />The area under the plasma concentration curve (AUC) for montelukast was decreased<br />approximately 40% in subjects with co-administration of phenobarbital. Since<br />montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised,<br />particularly in children, when montelukast is co-administered with inducers of CYP 3A4,<br />2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.<br />In vitro studies have shown that montelukast is a potent inhibitor of CYP 2C8. However,<br />data from a clinical drug-drug interaction study involving montelukast and rosiglitazone<br />(a probe substrate representative of medicinal products primarily metabolised by CYP<br />2C8) demonstrated that montelukast does not inhibit CYP 2C8 in vivo. Therefore,<br />montelukast is not anticipated to markedly alter the metabolism of medicinal products<br />metabolised by this enzyme (eg., paclitaxel, rosiglitazone, and repaglinide).<br />In vitro studies have shown that montelukast is a substrate of CYP 2C8, and to a less<br />significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving<br />montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil<br />increased the systemic exposure of montelukast by 4.4-fold. No routine dosage<br />adjustment of montelukast is required upon co-administration with gemfibrozil or other<br />potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an<br />increase in adverse reactions.<br />Based on in vitro data, clinically important drug interactions with less potent inhibitors of<br />CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the<br />systemic exposure of montelukast.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Animal studies do not indicate harmful effects with respect to effects on pregnancy or<br />embryonal/foetal development.<br />Limited data from available pregnancy databases do not suggest a causal relationship<br />between Montelukast Sodium and malformations (i.e. limb defects) that have been rarely<br />reported in worldwide post-marketing experience.<br />Montelukast Sodium may be used during pregnancy only if it is considered to be clearly<br />essential.<br />Breast-feeding<br />Studies in rats have shown that montelukast is excreted in milk. It is unknown whether<br />montelukast/metabolites are excreted in human milk.<br />Montelukast Sodium may be used in breast-feeding mothers only if it is considered to be<br />clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast Sodium has no or negligible influence on the ability to drive and use<br />machines. However, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies in patients with persistent asthma as<br />follows:<br /> 10 mg film-coated tablets in approximately 4,000 adult and adolescent patients 15<br />years of age and older<br /> 5 mg chewable tablets in approximately 1,750 paediatric patients 6 to 14 years of<br />age, and<br /> 4 mg chewable tablets in 851 paediatric patients 2 to 5 years of age.<br />Montelukast has been evaluated in a clinical study in patients with intermittent asthma as<br />follows:<br /> 4 mg granules and chewable tablets in 1038 paediatric patients 6 months to 5 years<br />of age&nbsp;The following drug-related adverse reactions in clinical studies were reported commonly<br />(&ge;1/100 to &lt;1/10) in patients treated with montelukast and at a greater incidence than<br />in patients treated with placebo:<br />Body System Class<br />Adult and Adolescent<br />Patients 15 years and<br />older<br />(two 12-week studies;<br />n=795)<br />Paediatric Patients<br />6 to 14 years&rsquo; old<br />(one 8-week study; n=201)<br />(two 56-week studies;<br />n=615)<br />Paediatric Patients<br />2 to 5 years&rsquo; old<br />(one 12-week study;<br />n=461)<br />(one 48-week study;<br />n=278)<br />Nervous system<br />disorders<br />headache headache --<br />Gastro-intestinal<br />disorders<br />abdominal pain -- abdominal pain<br />General disorders<br />and administration<br />site conditions<br />-- -- thirst&nbsp;With prolonged treatment in clinical trials with a limited number of patients for up to 2<br />years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the<br />safety profile did not change.<br />Cumulatively, 502 paediatric patients 2 to 5 years of age were treated with montelukast<br />for at least 3 months, 338 for 6 months or longer, and 534 patients for 12 months or<br />longer. With prolonged treatment, the safety profile did not change in these patients<br />either.<br />Tabulated list of Adverse Reactions<br />Adverse reactions reported in post-marketing use are listed, by System Organ Class and<br />specific Adverse Reactions, in the table below. Frequency Categories were estimated<br />based on relevant clinical trials.</p><p>System Organ Class Adverse Experience Term Frequency Category*<br />Infections and infestations upper respiratory infection&dagger; Very Common<br />Blood and lymphatic system<br />disorders<br />increased bleeding tendency Rare<br />Immune system disorder<br />hypersensitivity reactions<br />including anaphylaxis<br />Uncommon<br />hepatic eosinophilic infiltration Very Rare<br />Gastrointestinal disorders diarrhoea&Dagger;, nausea&Dagger;, vomiting&Dagger; Common<br />dry mouth, dyspepsia Uncommon&nbsp;- 18 -<br />System Organ Class Adverse Experience Term Frequency Category*<br />Psychiatric disorders<br />dream abnormalities including<br />nightmares, insomnia,<br />somnambulism, anxiety,<br />agitation including aggressive<br />behaviour or hostility,<br />depression, psychomotor<br />hyperactivity (including<br />irritability, restlessness,<br />tremor&sect;)<br />Uncommon<br />disturbance in attention,<br />memory impairment<br />Rare<br />hallucinations, disorientation,<br />suicidal thinking and behaviour<br />(suicidality)<br />Very Rare<br />Nervous system disorder<br />dizziness, drowsiness<br />paraesthesia/hypoesthesia,<br />seizure<br />Uncommon<br />Cardiac disorders palpitations Rare<br />Respiratory, thoracic and<br />mediastinal disorders<br />epistaxis Uncommon<br />Churg-Strauss Syndrome (CSS) Very Rare<br />Pulmonary eosinophilia Very Rare<br />Hepatobiliary disorders<br />elevated levels of serum<br />transaminases (ALT, AST)<br />Common<br />Hepatitis (including cholestatic,<br />hepatocellular, and mixedpattern<br />liver injury).<br />Very Rare<br />Skin and subcutaneous tissue<br />disorders<br />rash&Dagger; Common<br />bruising, urticaria, pruritus Uncommon<br />angiooedema Rare<br />erythema nodosum, erythema<br />multiforme<br />Very Rare<br />Musculoskeletal, connective tissue<br />and bone disorders<br />arthralgia, myalgia including<br />muscle cramps<br />Uncommon<br />General disorders and<br />administration site conditions<br />pyrexia&Dagger; Common<br />asthenia/fatigue, malaise,<br />oedema<br />Uncommon<br />*Frequency Category: Defined for each Adverse Experience Term by the incidence reported<br />in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10),<br />Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000).<br />&dagger; This adverse experience, reported as Very Common in the patients who received<br />montelukast, was also reported as Very Common in the patients who received placebo in<br />clinical trials.<br />&Dagger; This adverse experience, reported as Common in the patients who received montelukast,<br />was also reported as common in the patients who received placebo in clinical trials.<br />&sect; Frequency Category: Rare&nbsp;To report any side effect(s):<br />&bull; Saudi Arabia:<br /> The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br /> Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, montelukast has been administered at doses up to 200<br />mg/day to adult patients for 22 weeks and in short-term studies, up to 900 mg/day to<br />patients for approximately one week without clinically important adverse experiences.<br />There have been reports of acute overdose in post-marketing experience and clinical<br />studies with montelukast. These include reports in adults and children with a dose as<br />high as 1,000 mg (approximately 61 mg/kg in a 42 month old child).<br />The clinical and laboratory findings observed were consistent with the safety profile in<br />adults and paediatric patients. There were no adverse experiences in the majority of<br />overdose reports.<br />Symptoms of overdose<br />The most frequently occurring adverse experiences were consistent with the safety<br />profile of montelukast and included abdominal pain, somnolence, thirst, headache,<br />vomiting, and psychomotor hyperactivity.<br />Management of overdose<br />No specific information is available on the treatment of overdose with montelukast. It is<br />not known whether montelukast is dialysable by peritoneal- or haemo-dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Leukotriene receptor antagonist<br />ATC-Code: R03D C03<br />Mechanism of action<br />The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids<br />released from various cells including mast cells and eosinophils. These important proasthmatic<br />mediators bind to cysteinyl leukotriene receptors (CysLT) found in the human<br />airway and cause airway actions, including bronchoconstriction, mucous secretion,<br />vascular permeability, and eosinophil recruitment.<br />Pharmacodynamic effects<br />Montelukast is an orally active compound which binds with high affinity and selectivity to<br />the CysLT1 receptor. In clinical studies, montelukast inhibits bronchoconstriction due to<br />inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within 2 hours of<br />oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that<br />caused by montelukast. Treatment with montelukast inhibited both early- and late-phase<br />bronchoconstriction due to antigen challenge. Montelukast, compared with placebo,<br />decreased peripheral blood eosinophils in adult and paediatric patients.<br />In a separate study, treatment with montelukast significantly decreased eosinophils in<br />the airways (as measured in sputum). In adult and paediatric patients 2 to 14 years of<br />age, montelukast, compared with placebo, decreased peripheral blood eosinophils while<br />improving clinical asthma control.<br />Clinical efficacy and safety<br />In studies in adults, montelukast, 10 mg once daily, compared with placebo,<br />demonstrated significant improvements in morning FEV1 (10.4% vs 2.7% change from<br />baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from<br />baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from<br />baseline). Improvement in patient-reported daytime and nighttime asthma symptoms<br />scores was significantly better than placebo.<br />Studies in adults demonstrated the ability of montelukast to add to the clinical effect of<br />inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus<br />montelukast vs beclomethasone, respectively for FEV1: 5.43% vs 1.04%; &beta;-agonist use:&nbsp;-8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a<br />spacer device), montelukast demonstrated a more rapid initial response, although over<br />the 12-week study, beclomethasone provided a greater average treatment effect (%<br />change from baseline for montelukast vs beclomethasone, respectively for FEV1:7.49% vs<br />13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone,<br />a high percentage of patients treated with montelukast achieved similar clinical responses<br />(e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV1 of<br />approximately 11% or more over baseline while approximately 42% of patients treated<br />with montelukast achieved the same response).<br />In a 12-week, placebo-controlled study in paediatric patients 2 to 5 years of age,<br />montelukast 4 mg once daily improved parameters of asthma control compared with<br />placebo irrespective of concomitant controller therapy (inhaled/nebulised corticosteroids<br />or inhaled/nebulised sodium cromoglycate). Sixty percent of patients were not on any<br />other controller therapy. Montelukast improved daytime symptoms (including coughing,<br />wheezing, trouble breathing and activity limitation) and nighttime symptoms compared<br />with placebo. Montelukast also decreased &ldquo;as needed&rdquo;&beta;-agonist use and corticosteroid<br />rescue for worsening asthma compared with placebo.<br />Patients receiving montelukast had more days without asthma than those receiving<br />placebo. A treatment effect was achieved after the first dose.<br />In a 12-month, placebo-controlled study in paediatric patients 2 to 5 years of age with<br />mild asthma and episodic exacerbations, montelukast 4 mg once daily significantly<br />(p&le;0.001) reduced the yearly rate of asthma exacerbation episodes (EE) compared with<br />placebo (1.60 EE vs. 2.34 EE, respectively), [EE defined as &ge;3 consecutive days with<br />daytime symptoms requiring &beta;-agonist use, or corticosteroids (oral or inhaled), or<br />hospitalisation for asthma]. The percentage reduction in yearly EE rate was 31.9%, with a<br />95% CI of 16.9, 44.1.<br />In a placebo-controlled study in paediatric patients 6 months to 5 years of age who had<br />intermittent asthma but did not have persistent asthma, treatment with montelukast was<br />administered over a 12-month period, either as a once-daily 4 mg regimen or as a series<br />of 12-day courses that each were started when an episode of intermittent symptoms<br />began. No significant difference was observed between patients treated with montelukast<br />4 mg or placebo in the number of asthma episodes culminating in an asthma attack,&nbsp;defined as an asthma episode requiring utilization of health-care resources such as an<br />unscheduled visit to a doctor&#39;s office, emergency room, or hospital; or treatment with<br />oral, intravenous, or intramuscular corticosteroid.<br />In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once<br />daily, compared with placebo, significantly improved respiratory function (FEV1 8.71% vs<br />4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline)<br />and decreased &ldquo;as-needed&rdquo; &beta;-agonist use (-11.7% vs +8.2% change from baseline).<br />In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on<br />asthma control in paediatric patients 6 to 14 years of age with mild persistent asthma,<br />montelukast was non-inferior to fluticasone in increasing the percentage of asthma<br />rescue-free days (RFDs), the primary endpoint. Averaged over the 12-month treatment<br />period, the percentage of asthma RFDs increased from 61.6 to 84.0 in the montelukast<br />group and from 60.9 to 86.7 in the fluticasone group.<br />The between group difference in LS mean increase in the percentage of asthma RFDs was<br />statistically significant (-2.8 with a 95% CI of -4.7, -0.9), but within the limit pre-defined<br />to be clinically not inferior. Both montelukast and fluticasone also improved asthma<br />control on secondary variables assessed over the 12 month treatment period:<br />FEV1 increased from 1.83 L to 2.09 L in the montelukast group and from 1.85 L to 2.14 L<br />in the fluticasone group. The between-group difference in LS mean increase in FEV1 was -<br />0.02 L with a 95% CI of -0.06, 0.02. The mean increase from baseline in % predicted<br />FEV1 was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone<br />treatment group. The difference in LS means for the change from baseline in the %<br />predicted FEV1 was significant: -2.2% with a 95% CI of -3.6, -0.7.<br />The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the<br />montelukast group, and from 38.5 to 12.8 in the fluticasone group. The between group<br />difference in LS means for the percentage of days with &beta;-agonist use was significant: 2.7<br />with a 95% CI of 0.9, 4.5.<br />The percentage of patients with an asthma attack (an asthma attack being defined as a<br />period of worsening asthma that required treatment with oral steroids, an unscheduled<br />visit to the doctor&#39;s office, an emergency room visit, or hospitalisation) was 32.2 in the&nbsp;montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being<br />significant: equal to 1.38 (1.04, 1.84).<br />The percentage of patients with systemic (mainly oral) corticosteroid use during the study<br />period was 17.8% in the montelukast group and 10.5% in the fluticasone group. The<br />between group difference in LS means was significant: 7.3% with a 95% CI of 2.9; 11.7.<br />Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a<br />12-week study in adults (maximal fall in FEV1 22.33% for montelukast vs 32.40% for<br />placebo; time to recovery to within 5% of baseline FEV1 44.22 min vs 60.64 min). This<br />effect was consistent throughout the 12-week study period.<br />Reduction in EIB was also demonstrated in a short term study in paediatric patients 6 to<br />14 years of age (maximal fall in FEV1 18.27% vs 26.11%; time to recovery to within 5%<br />of baseline FEV1 17.76 min vs 27.98 min). The effect in both studies was demonstrated at<br />the end of the once-daily dosing interval.<br />In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral<br />corticosteroids, treatment with montelukast, compared with placebo, resulted in<br />significant improvement in asthma control (FEV1 8.55% vs -1.74% change from baseline<br />and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated<br />tablet, the mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after<br />administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral<br />bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were<br />demonstrated in clinical trials where the 10 mg film-coated tablet was administered<br />without regard to the timing of food ingestion.<br />For the 5 mg chewable tablet, the Cmax is achieved in 2 hours after administration in<br />adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63%<br />by a standard meal.<br />After administration of the 4 mg chewable tablet to paediatric patients 2 to 5 years of age<br />in the fasted state, Cmax is achieved 2 hours after administration. The mean Cmax is<br />66% higher while mean Cmin is lower than in adults receiving a 10 mg tablet.&nbsp;Distribution<br />Montelukast is more than 99% bound to plasma proteins. The steady-state volume of<br />distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled<br />montelukast indicate minimal distribution across the blood-brain barrier. In addition,<br />concentrations of radiolabelled material at 24 hours post-dose were minimal in all other<br />tissues.<br />Biotransformation<br />Montelukast is extensively metabolised. In studies with therapeutic doses, plasma<br />concentrations of metabolites of montelukast are undetectable at steady state in adults<br />and children.<br />Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally<br />CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of<br />CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy<br />subjects that received 10 mg montelukast daily.<br />Based on in vitro results in human liver microsomes, therapeutic plasma concentrations of<br />montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The<br />contribution of metabolites to the therapeutic effect of montelukast is minimal.<br />Elimination<br />The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an<br />oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day<br />faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of<br />montelukast oral bioavailability, this indicates that montelukast and its metabolites are<br />excreted almost exclusively via the bile.<br />Characteristics in Patients<br />No dosage adjustment is necessary for the elderly or mild to moderate hepatic<br />insufficiency. Studies in patients with renal impairment have not been undertaken.<br />Because montelukast and its metabolites are eliminated by the biliary route, no dose<br />adjustment is anticipated to be necessary in patients with renal impairment. There are no<br />data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency<br />(Child-Pugh score &gt;9).&nbsp;With high doses of montelukast (20- and 60-fold the recommended adult dose), a<br />decrease in plasma theophylline concentration was observed. This effect was not seen at<br />the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose,<br />phosphorus and triglycerides were observed which were transient in nature. The signs of<br />toxicity in animals were increased excretion of saliva, gastro-intestinal symptoms, loose<br />stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the<br />systemic exposure seen at the clinical dosage.<br />In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the<br />systemic exposure seen at the clinical dose).<br />In animal studies, montelukast did not affect fertility or reproductive performance at<br />systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A<br />slight decrease in pup body weight was noted in the female fertility study in rats at 200<br />mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher<br />incidence of incomplete ossification, compared with concurrent control animals, was seen<br />at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No<br />abnormalities were seen in rats. Montelukast has been shown to cross the placental<br />barrier and is excreted in breast milk of animals.<br />No deaths occurred following a single oral administration of montelukast sodium at doses<br />up to 5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats,<br />respectively), the maximum dose tested. This dose is equivalent to 25,000 times the<br />recommended daily adult human dose (based on an adult patient weight of 50 kg).<br />Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light<br />spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic<br />exposure).<br />Montelukast was neither mutagenic in in vitro and in vivo tests nor tumorigenic in rodent<br />species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6. Pharmaceutical Particulars:<br />6.1. List of excipients:<br />S. NO. MATERIAL FUNCTION<br />Dry Mixing<br />1. Mannitol (Pearlitol 25C) Ph.Eur. Diluent<br />2. Croscarmellose Sodium (Ac-di-Sol) Ph.Eur. Disintegrant<br />3. Hydroxypropyl Cellulose (Klucel EXF) Ph.Eur. Binder<br />Granulation<br />4. Hydroxypropyl Cellulose (Klucel EXF) Ph.Eur. Binder<br />5. Ferric Oxide (Sicovit Red 30E172) USP/NF Colorant<br />6. Purified Water IHS/USP/ Ph.Eur. Solvent<br />7. Purified Water (If required) IHS/USP/ Ph.Eur. Solvent<br />Extra Granular<br />8. Cellulose Microcrystalline (Avicel PH 112) Ph.Eur. Diluent<br />9. Mannitol (Pearlitol SD 100) Ph.Eur. Diluent<br />10. Ferric Oxide (Sicovit Red 30E172) USP/NF Colorant<br />11. Aspartame Ph.Eur. Sweetener<br />12. ART Cherry Flavor (SD 594) IHS Flavoring Agen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.2. Incompatibilities:<br />None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The Chewable tablets are packed in Alu/Alu blisters and placed in a printed carton along<br />with a pack insert.<br />Pack size: 30&rsquo;s</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Neopharma,
Plot No, A1 89-95, Industrial City of Abu Dhabi,
Mussafah, P.O.Box: 72900
Abu Dhabi, UAE.
6.7 Marketing Authorization Holder:
Neopharma,
Plot No, A1 89-95, Industrial City of Abu Dhabi,
Mussafah, P.O.Box: 72900
Abu Dhabi, UAE.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 December 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>